The Biomet deal may be in peril.

Shareholders of Biomet, makers of medical devices such as hip and knee replacements, are scheduled to vote on a buyout next week. A consortium of private equity firms with an impressive list of names, including Blackstone Group, Kohlberg Kravis Roberts & Co., TPG, and Goldman Sachs Group's private-equity arm, plans on buying Biomet for $44/share.

Back in December when they made the bid, it was a good deal. However, Biomet shares have gone up since then, and Institutional Shareholder Services (an advisory firm) recommended that shareholders reject the offer. In a report, the firm said, "There is little takeover premium in the current $44 offer price."

Financial analysts think the deal is in jeopardy, but the biomed industry seems to think the deal may still have a chance.

We'll find out soon enough: Shareholders vote on June 8.

A deal to sell one of Indiana's largest medical-device makers, Biomet, to a group of private investors is coming under a cloud, just a week before shareholders are scheduled to vote on the deal.

And now some analysts are wondering if Biomet, which has been looking for a buyer for more than a year, still can persuade shareholders to approve the deal or if it will be forced to try to negotiate a higher price.

(Continue reading this story on The Indianapolis Star)

Next article » Once Maligned, Now Benign

Previous article « Muslim Blasts Merrill